<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2021.113204</article-id><article-id pub-id-type="publisher-id">ACM-41392</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20210300000_27480835.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  肝星状细胞与肝纤维化及其逆转的研究进展
  Advances in Hepatic Stellate Cells and Hepatic Fibrosis and Its Reverse
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>郑</surname><given-names>万明</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>吴</surname><given-names>怡林</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>龚</surname><given-names>建平</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>重庆市渝北区中医院普通外科，重庆</addr-line></aff><aff id="aff3"><addr-line>重庆医科大学附属第二医院肝胆外科，重庆</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>04</day><month>03</month><year>2021</year></pub-date><volume>11</volume><issue>03</issue><fpage>1420</fpage><lpage>1428</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    肝纤维化是肝硬化进展的早期步骤，感染、毒性/药物诱导，代谢和自身免疫都可以导致肝纤维化。而在肝纤维化的过程中，肝星状细胞(hepatic stellate cells, HSCs)发挥着关键作用，活化的肝星状细胞是肝纤维化时过量细胞外基质的主要来源，通过TGFβ-Smad信号通路、PDGF信号通路、NF-κB信号通路等激活静息状态的肝星状细胞，激活的HSCs (activated hepatic stellate cells, aHSCs)大量增殖发生表型改变并分泌过多的细胞外基质沉积于肝脏。传统观点认为肝硬化是不可逆的疾病，然而最近的证据表明，通过抑制HSCs的活化和增殖，免疫清除、细胞凋亡衰老等机制参与活化HSCs的清除以促进肝纤维化的逆转。并将HSCs作为肝纤维化治疗的靶点，研究发现无论是天然提取物或是合成化合物，都具有一定的抗纤维化作用。本文将对肝星状细胞与肝纤维化及其逆转的相关关系，以及与HSCs相关的肝纤维化治疗的研究进展进行简要综述。
    Liver fibrosis is an early step in the progression of cirrhosis. It can be caused by infection, toxicity/drug induction, metabolism and autoimmunity. In the process of liver fibrosis, hepatic stellate cells play a key role and are the main source of excessive extracellular matrix during liver fibrosis. Through TGFβ-Smad, PDGF, NF-κB and other signal pathways, the activated hepatic stellate cells proliferate and secrete excessive extracellular matrix which deposits in the liver. The traditional view is that cirrhosis is an irreversible disease. However, recent evidence suggests that mechanisms such as inhibiting the activation and proliferation of HSCs, immune clearance, apoptosis and senescence are involved in the clearance of activated HSCs to promote the reversal of liver fibrosis. HSCs were used as the therapeutic target for liver fibrosis. It is found that both natural product extract and synthetic compound have certain anti-fibrosis effect. Here we briefly review the correlation between hepatic stellate cells and hepatic fibrosis and its reversal, as well as the research progress in the treatment of hepatic fibrosis related to HSCs. 
  
 
</p></abstract><kwd-group><kwd>HSCs，肝硬化，信号传导, Hepatic Stellate Cells</kwd><kwd> Hepatic Fibrosis</kwd><kwd> Signal Transduction</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>肝纤维化是肝硬化进展的早期步骤，感染、毒性/药物诱导，代谢和自身免疫都可以导致肝纤维化。而在肝纤维化的过程中，肝星状细胞(hepatic stellate cells, HSCs)发挥着关键作用，活化的肝星状细胞是肝纤维化时过量细胞外基质的主要来源，通过TGFβ-Smad信号通路、PDGF信号通路、NF-κB信号通路等激活静息状态的肝星状细胞，激活的HSCs (activated hepatic stellate cells, aHSCs)大量增殖发生表型改变并分泌过多的细胞外基质沉积于肝脏。传统观点认为肝硬化是不可逆的疾病，然而最近的证据表明，通过抑制HSCs的活化和增殖，免疫清除、细胞凋亡衰老等机制参与活化HSCs的清除以促进肝纤维化的逆转。并将HSCs作为肝纤维化治疗的靶点，研究发现无论是天然提取物或是合成化合物，都具有一定的抗纤维化作用。本文将对肝星状细胞与肝纤维化及其逆转的相关关系，以及与HSCs相关的肝纤维化治疗的研究进展进行简要综述。</p></sec><sec id="s2"><title>关键词</title><p>HSCs，肝硬化，信号传导</p></sec><sec id="s3"><title>Advances in Hepatic Stellate Cells and Hepatic Fibrosis and Its Reverse<sup> </sup></title><p>Wanming Zheng<sup>1</sup>, Yilin Wu<sup>2</sup>, Jianping Gong<sup>2*</sup></p><p><sup>1</sup>Department of General Surgery, Chongqing Yubei District Hospital of Traditional Chinese Medicine, Chongqing</p><p><sup>2</sup>Department of Hepatobiliary Surgery, The Second Affiliated Hospital of Chongqing Medical University, Chongqing</p><p><img src="//html.hanspub.org/file/87-1572070x5_hanspub.png" /></p><p>Received: Feb. 25<sup>th</sup>, 2021; accepted: Mar. 12<sup>th</sup>, 2021; published: Mar. 31<sup>st</sup>, 2021</p><p><img src="//html.hanspub.org/file/87-1572070x6_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Liver fibrosis is an early step in the progression of cirrhosis. It can be caused by infection, toxicity/drug induction, metabolism and autoimmunity. In the process of liver fibrosis, hepatic stellate cells play a key role and are the main source of excessive extracellular matrix during liver fibrosis. Through TGFβ-Smad, PDGF, NF-κB and other signal pathways, the activated hepatic stellate cells proliferate and secrete excessive extracellular matrix which deposits in the liver. The traditional view is that cirrhosis is an irreversible disease. However, recent evidence suggests that mechanisms such as inhibiting the activation and proliferation of HSCs, immune clearance, apoptosis and senescence are involved in the clearance of activated HSCs to promote the reversal of liver fibrosis. HSCs were used as the therapeutic target for liver fibrosis. It is found that both natural product extract and synthetic compound have certain anti-fibrosis effect. Here we briefly review the correlation between hepatic stellate cells and hepatic fibrosis and its reversal, as well as the research progress in the treatment of hepatic fibrosis related to HSCs.</p><p>Keywords:Hepatic Stellate Cells, Hepatic Fibrosis, Signal Transduction</p><disp-formula id="hanspub.41392-formula134"><graphic xlink:href="//html.hanspub.org/file/87-1572070x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/87-1572070x8_hanspub.png" /> <img src="//html.hanspub.org/file/87-1572070x9_hanspub.png" /></p></sec><sec id="s5"><title>1. 前言</title><p>肝纤维化是一个动态的过程，其特征是细胞外基质(extracellular matrix, ECM)或瘢痕的净积累，肝内纤维细胞外基质的逐渐积累是机体对各种有害刺激的持续创伤愈合反应，包括病毒感染、药物毒性、酒精和自身免疫性肝病。肝纤维化是肝硬化进展的早期步骤，由于缺乏有效的治疗方法，肝硬化是目前世界性的重大健康问题 [<xref ref-type="bibr" rid="hanspub.41392-ref1">1</xref>] [<xref ref-type="bibr" rid="hanspub.41392-ref2">2</xref>]。所幸的是在酒精或胆管结扎(BDL)导致的肝纤维化患者和实验性肝纤维化模型中，我们发现去除致病因子后，肝纤维化是可逆的。大量研究证明，无论是在肝纤维化的发生或是逆转中，肝脏的肝星状细胞(hepatic stellate cells, HSCs)都发挥着重要的作用。那么肝星状细胞是怎样参与肝纤维化及其逆转，是否可为临床提供潜在的治疗思路？本文将对肝星状细胞与肝纤维化及其逆转的相关关系，以及与HSCs相关的肝纤维化治疗的研究进展进行简要综述。</p></sec><sec id="s6"><title>2. 肝星状细胞与肝纤维化</title><sec id="s6_1"><title>2.1. 肝纤维化</title><p>病毒感染、酒精性肝病和非酒精性脂肪性肝炎(non-alcoholic steatohepatitis, NASH)都可以导致细胞外基质沉积，而这种沉积是肝星状细胞转化为活化的肌成纤维细胞而导致的，肝损伤导致HSCs活化，HSCs通过分化为具有迁移和增殖能力的肌成纤维细胞，生成基质蛋白促进伤口愈合 [<xref ref-type="bibr" rid="hanspub.41392-ref3">3</xref>] [<xref ref-type="bibr" rid="hanspub.41392-ref4">4</xref>]，肝星状细胞位于肝细胞和窦内皮细胞之间的窦间隙，是激活的肌成纤维细胞和门脉成纤维细胞的主要来源，能够驱动纤维化过程。正常肝脏HSCs处于静止状态，静止状态的肝星状细胞(即qHSCs)主要作为维生素A的储备，此时的ECM是由包括胶原在内的大分子组成，可以由多种酶，主要是由基质金属蛋白酶(matrix metalloproteinase MMPs)降解，因此在健康的肝脏，细胞外基质被有效降解，没有积累导致纤维化 [<xref ref-type="bibr" rid="hanspub.41392-ref5">5</xref>]。而当肝脏受到损伤，炎症介质促进HSCs活化并分化为肌成纤维细胞，活化状态的肝星状细胞(aHSCs)是肝脏胶原蛋白的主要来源，可大量分泌ECM蛋白、金属蛋白酶的组织抑制剂和基质金属蛋白酶，诱导肝脏结构重构，从而导致肝纤维化的发生和进展 [<xref ref-type="bibr" rid="hanspub.41392-ref6">6</xref>]。</p></sec><sec id="s6_2"><title>2.2. 肝纤维化中HSCs活化的主要信号通路</title><p>HSCs在肝纤维化的过程中扮演着起始角色，损伤/发炎的肝组织微环境中的几个细胞事件以及肝外因素可直接诱导肝星状细胞活化，其病因可能是特异性的，也可能是独立的，某些病理因素如TGFβ1、PDGF、酒精、毒素、脂肪变性的刺激均可导致肝星状细胞的活化，同时慢性肝病进展至肝纤维化是一个由多种细胞因子，多种细胞信号转导通路参与的复杂过程。了解影响HSCs活化增殖的有关信号转导通路的作用机制，有助于更好理解HSCs与肝纤维化之间的关系。而在这些纷繁复杂的信号通路中，最为广泛研究的是：TGFβ-Smad信号通路、PDGF信号通路和NF-κB信号通路。</p><sec id="s6_2_1"><title>2.2.1. TGFβ-Smad信号通路</title><p>最近的研究表明，TGF-β/Smad信号在肝纤维化的进展中起着至关重要的作用。TGFβ共有3种类型：TGFβ1，TGFβ2和TGFβ3，这三种类型中肝脏含量最高且具有生物活性的是转化生长因子-β1 (transfor ming growth factor, TGF-β1)，其以自分泌或旁分泌的方式发挥作用，由库否细胞、窦性内皮细胞和肝细胞产生，而TGF-β1已被确认为是最能促纤维化的细胞因子。在肝纤维化的发生发展中，TGF-β1的主要作用是促进ECM合成，提高胶原蛋白在肝星状细胞中的表达，促使HSCs分泌金属蛋白酶组织抑制物，下调降解蛋白酶的合成，阻止新合成的细胞外基质分解而减少ECM的降解，使ECM沉积增多，加速肝纤维化的发展。TGF-β1这一连串的作用奠定了其在肝纤维化中的重要作用 [<xref ref-type="bibr" rid="hanspub.41392-ref7">7</xref>]。在TGF-β信号通路中，关键的信号传导分子是胞质蛋白Smad，该通路通过Smad 和非Smad通路引起多种生物学效应，包括由于肝损伤引起的高水平的TGF-β，激活HSCs促进其肌成纤维细胞转化。当TGF-β1活化后，与TGF-βII型受体(TGFβRII)结合并导致I型受体(TGFβRI)的激活，激活的I型受体能够磷酸化Smad2和Smad3并与Smad4形成复合体。磷酸化的Smad2/3/4形成复合体被直接运往细胞核并介导促纤维化基因的转录调控 [<xref ref-type="bibr" rid="hanspub.41392-ref8">8</xref>] [<xref ref-type="bibr" rid="hanspub.41392-ref9">9</xref>]。Smad是调节纤维发生TGF-β1信号的蛋白质家族，不同于Smad2/3/4，Smad7蛋白质被称为抑制性Smad (I-Smad)，它能够通过与TGFβRI结合从而抑制Smad2激活，或者与其他效应器结合诱导TGFβRI退化等方式，从而达到抑制TGF-β1/Smad信号通路的效果，当Smad7表达被抑制，可导致TGF-β持续激活，引起肝纤维化 [<xref ref-type="bibr" rid="hanspub.41392-ref10">10</xref>]。</p></sec><sec id="s6_2_2"><title>2.2.2. PDGF信号通路</title><p>血小板源性生长因子(platelet-derived growth factor, PDGF)是重要的促肝纤维化因子，PDGF促进胶原的产生和沉积，并将HSCs转化为肌成纤维细胞，PDGF的过表达可以驱动HSCs的增殖、运动和趋化，阻断PDGF信号通路能够抑制HSCs增殖，有效地改善肝脏纤维化 [<xref ref-type="bibr" rid="hanspub.41392-ref11">11</xref>]。PDGF以5种亚型存在：PDGF-AA、PDGF-AB、PDGF-BB、PDGF-CC和PDGF-DD。PDGF的细胞效应需要细胞表面受体酪氨酸激酶(receptor tyrosine kinase RTK)的作用，即血小板源生长因子受体(PDGF receptor)，包括血小板源生长因子受体α (PDGFRα)和血小板源生长因子受体β (PDGFR&#223;)，PDGFRα和PD GFRβ各含有五个结构域：免疫球蛋白样结构域、跨膜结构域、ATP结合位点、细胞内亲水激酶结构域和细胞质尾 [<xref ref-type="bibr" rid="hanspub.41392-ref12">12</xref>]。PDGFR&#223;和PDGFRα在慢性肝损伤的肝星状细胞活化和纤维化中扮演重要的角色，其与PDGF结合后，形成αα、αβ和ββ二聚体并触发每个受体特定残基的酪氨酸磷酸化，其磷酸化提高了催化效率，并作为信号分子(包括其他激酶和非酶适配器分子)的结合位点 [<xref ref-type="bibr" rid="hanspub.41392-ref13">13</xref>] PDGF受体在健康肝脏中的表达较低，但在损伤过程中随着肝星形细胞的活化而表达显著增加，相比正常的肝脏，在纤维化肝脏细胞中PDGFRα表达增加 [<xref ref-type="bibr" rid="hanspub.41392-ref14">14</xref>]，PDGFβ受体(PDGFRβ)的表达是在HSCs激活的起始过程中诱导的，并通过ERK、AKT和NF-κB途径增强炎症和纤维化对化学损伤的反应。在许多研究设计中，都将PDGF作为一种HSCs的激活剂，从而进行HSCs的相关研究，若是能够有效的下调PDGF/PDGFR信号通路，便能有效地缓解肝纤维化。</p></sec><sec id="s6_2_3"><title>2.2.3. NF-κB信号通路</title><p>NF-κB信号通路是PI3K/AKT信号通路的分支，激活PI3K/AKT通路可以直接激活它，是一个高度保守通路，主要调节免疫和炎症反应。核因子NF-κB (nuclear factor-κB, NF-κB)是一种具有转录激活功能的蛋白质，属于NF-κB/Rel蛋白家族，NF-κB家族由NF-κB1 (又称p50)、NF-κB2 (又称p52)、RelA (又称p65)、RelB和c-Rel共5个成员组成。当细胞面临各种刺激，如病毒和细菌感染、坏死细胞产物、DNA损伤、氧化应激和促炎细胞因子时，NF-κB通路被激活，并启动针对炎症或细菌、病毒或其他致病微生物入侵的免疫应答，NF-κB的激活主要涉及经典和非经典(或称替代)通路，经典通路激活的主要机制是通过激活经典IK K激酶，而非经典通路则是通过NIK (NF-κB inducing kinase)和IKKα加工NF-κB2前体P100为P52来实现 [<xref ref-type="bibr" rid="hanspub.41392-ref15">15</xref>] [<xref ref-type="bibr" rid="hanspub.41392-ref16">16</xref>]。TGF-β和PDGF是介导肝纤维化形成的重要细胞因子，但TGF-β和PDGF依赖的成纤维细胞模型无法解释炎症介质在肝纤维化发生中的作用，但有研究提示TLR4-MyD88–NF-κB轴对TGF-β信号的调节作用可能为促炎和促纤维化信号提供了一种新的联系，Toll样受体4的激活不仅能导致肝脏炎症也能促进其纤维化，而这种纤维化不是以以往认可的库否细胞为靶点，而是以HSCs为靶点，通过激活NF-κB信号通路调节TGF-β信号 [<xref ref-type="bibr" rid="hanspub.41392-ref17">17</xref>]。激活的肝星状细胞中NF-κB活性增加，因此，许多NF-κB应答基因是既定表达在活化肝星状细胞，而不是在静止肝星状细胞，许多物质都可以通过NF-κB信号调节HSCs活性。</p></sec></sec></sec><sec id="s7"><title>3. 肝星状细胞与肝纤维化逆转</title><sec id="s7_1"><title>3.1. 肝纤维化的可逆性</title><p>传统观点认为肝硬化是不可逆的疾病，然而最近的证据表明，即使在肝纤维化晚期，纤维化也是可逆的，其潜在机制包括炎症环境的转换、活化的HSCs消除或消退以及细胞外基质的降解，种种研究表明，肝纤维化逆转正从想象走向现实 [<xref ref-type="bibr" rid="hanspub.41392-ref18">18</xref>]。在患者和动物模型中，当致病条件(包括酒精、肝炎病毒、化学物质、胆道梗阻和肥胖)消除后，纤维化可以逆转。在人类中，肝纤维化的逆转可以发生在成功治疗基础疾病之后。纤维化消退现在已成为临床的现实，对成功治疗的不同病因的慢性肝病患者的活检样本进行的系列评估表明，肝纤维化是一个动态的、双向的过程，具有恢复和重建的内在能力，不同的病因的肝纤维化在临床实践中都有着相应的临床恢复的证据和研究结果 [<xref ref-type="bibr" rid="hanspub.41392-ref19">19</xref>]。</p></sec><sec id="s7_2"><title>3.2. 与HSCs相关的肝纤维化逆转的分子机制</title><p>肝纤维化的形成主要取决于细胞外基质的合成与降解之间的动态平衡，当合成大于降解时，肝内胶原纤维增加，纤维化逐渐形成，如果降解大于合成，纤维化可逐渐逆转。而肝内胶原主要由ECM构成，ECM又主要来源于HSCs，因此，在肝纤维化逆转过程中HSCs作用的分子机制十分关键，抑制HSCs的活化和增殖对肝纤维化逆转治疗具有重要意义，同时免疫清除、细胞凋亡、细胞衰老等机制参与活化HSCs的清除，那么理论上刺激这些机制也可以促进肝纤维化的逆转 [<xref ref-type="bibr" rid="hanspub.41392-ref20">20</xref>]。</p><sec id="s7_2_1"><title>3.2.1. 抑制HSCs的活化和增殖</title><p>HSCs在多种因素的作用下发生活化增殖，并与肝纤维化的发生发展有着紧密的关系，那么通过各种途径阻碍HSCs的活化增殖是第一选择。而在前文中介绍的HSCs活化信号通路中有大量的明星分子，如TGF-β1，PDGF等，都在纤维化过程中起核心作用，那么通过药物等手段抑制这些关键分子，阻断信号通路传递就能有效的抑制HSCs的活化增殖。活化的TGF-β能够通过激活肝星状细胞促进进肝纤维化，有研究证明，有效地抑制TGF-β及其活化的肝星状细胞，能够防止小鼠肝纤维化。细胞外基质蛋白1 (extracellular matrix protein 1 ECM1)被发现在正常的小鼠肝组织中，能够使细胞外基质中的TGF-β处于非激活状态，有效阻止肝星状细胞的激活，而在患者的肝脏组织和CCL4诱导的肝纤维化小鼠模型中，ECM1的水平与纤维化的严重程度呈负相关。实验者提出增加肝脏中ECM1水平的策略来用于纤维化的治疗 [<xref ref-type="bibr" rid="hanspub.41392-ref21">21</xref>]。在PDGF信号通路中，有学者通过PDGFRα特异性抑制性单克隆抗体抑制PDGF-α和PDGF-β介导的信号转导，发现能抑制下游细胞信号通路，并能有效减少HSCs的增殖和迁移 [<xref ref-type="bibr" rid="hanspub.41392-ref14">14</xref>]。PDGF信号通路是通过酪氨酸磷酸化发挥作用，那么小分子酪氨酸激酶抑制剂，包括伊马替尼、索拉非尼、尼洛替尼和舒尼替尼，在体外培养的人肝纤维化组织中，都能够抑制活化的肝星状细胞增殖和成纤维特性 [<xref ref-type="bibr" rid="hanspub.41392-ref22">22</xref>]。生长抑素类似物奥曲肽(Otreotide)被报道具有抗肝纤维化作用，探索其体内体外的抗纤维化作用。结果表明，奥曲肽对CCl4诱导的大鼠肝纤维化模型的肝纤维化标记物(包括α平滑肌肌动蛋白(α-SMA)和I型胶原)的蛋白和mRNA的表达有明显的下调作用，一个体外实验结果表明，奥曲肽能够以浓度依赖性的方式抑制TGF-β1处理的LX-2细胞(即HSCs)的活化和增殖来减轻肝纤维化 [<xref ref-type="bibr" rid="hanspub.41392-ref23">23</xref>]。YAP (Yes-associated protein)是Hippo信号通路中重要的下游蛋白，在细胞增殖、凋亡、侵袭和迁移等方面发挥重要作用，同时YAP在肝纤维化逆转中通过调节HSCs的增殖、凋亡发挥作用。学者发现在体内体外纤维化模型中，YAP表达都增高，因此学者沉默YAP表达，发现能够抑制TGF-β1刺激的HSC-T6细胞的激活和增殖，并且活化的HSC-T6细胞经YAP沉默后，细胞凋亡略有增强 [<xref ref-type="bibr" rid="hanspub.41392-ref24">24</xref>]。</p></sec><sec id="s7_2_2"><title>3.2.2. 免疫清除</title><p>HSCs可通过促进炎症细胞募集来增强损伤肝脏的炎症反应，然而相对地，免疫细胞可拮抗甚至逆转肝纤维化，从而减少活化HSCs的数量。巨噬细胞在肝纤维化中具有调节基质沉积和分解双向作用，巨噬细胞在肝损伤中的不同极化类型具有不同的作用，M0和M1巨噬细胞均能明显改善肝纤维化，且M1的治疗作用强于M0，M1巨噬细胞能调节肝脏微环境，从而影响内源性巨噬细胞和自然杀伤细胞活化，减少肝星状细胞的数量和活化，促进HSCs凋亡 [<xref ref-type="bibr" rid="hanspub.41392-ref25">25</xref>] [<xref ref-type="bibr" rid="hanspub.41392-ref26">26</xref>]。自然杀伤(Natural killer, NK)和自然杀伤样T (Natural killer-like T, NKT)细胞活化后能直接杀伤靶细胞。自然杀伤细胞已被证明能通过多种机制发挥抗纤维化作用，包括表达IFN-c和/或死亡配体(如肿瘤坏死因子相关凋亡诱导配体(TRAIL)和FasL)，动物模型的最新证据提示：NK细胞能够选择性杀伤早期或衰老激活的肝星状细胞和产生抗纤维化细胞因子，例如：IFN-γ，借此诱导HSCs凋亡和细胞周期阻滞并进而抑制肝纤维化，在抑制肝纤维化中发挥重要作用。与NK细胞介导的抗纤维化作用不同，NKT细胞在肝纤维化发病机制中的作用更为复杂，NKT细胞可以通过选择性地去除活化HSCs释放的IL-30以及促进IFN-γ释放诱导肝星状细胞的凋亡来改善肝纤维化 [<xref ref-type="bibr" rid="hanspub.41392-ref27">27</xref>]。包括Th1、Th2、Th17在内的CD4+ T淋巴细胞和调节性T细胞(regulatory T cells, Tregs)都能产生直接或间接作用，并最终促进纤维化逆转，B淋巴细胞可直接或间接作用于HSCs、NK细胞或CD4+ T淋巴细胞发挥抗纤维化作用 [<xref ref-type="bibr" rid="hanspub.41392-ref28">28</xref>]。</p></sec><sec id="s7_2_3"><title>3.2.3. 细胞凋亡、细胞衰老</title><p>活化的肝细胞凋亡是控制肝纤维化的重要途径，因此诱导HSCs凋亡被认为是潜在的抗纤维化治疗手段，通过细胞凋亡来清除活化的肝星状细胞，对肝纤维化的可逆性至关重要。多种元素参与HSCs凋亡过程，如Bcl-2蛋白家族，分为抗凋亡蛋白(Bcl-2, Bcl-xL, Bcl-x, Bcl-XL, Bcl-XS, Bcl-W, BAG)和促凋亡蛋白(Bax, Bak, BH3, Bid, Bad, Bim, Bik, Blk)，许多促进凋亡的药物通过抑制BcL-2表达，增加caspase3、caspase9和细胞色素c的表达，从而诱导凋亡 [<xref ref-type="bibr" rid="hanspub.41392-ref29">29</xref>]。同时有研究证明，在肝纤维化逆转过程中，肝星状细胞有丝分裂增强，细胞凋亡增加。抑制有丝分裂能够抑制HSCs的凋亡，从而加重小鼠肝纤维化，相反有丝分裂激活能够诱导HSCs凋亡。此外，学者证实BCL-B作为BCL-2家族的一员，是介导有丝分裂相关凋亡的一个调节者，敲除BCL-B导致HSCs细胞凋亡和有丝分裂增加，而BCL-B的过表达则产生相反的作用 [<xref ref-type="bibr" rid="hanspub.41392-ref30">30</xref>]。</p><p>细胞衰老是一种受基因控制的生理机制，限制细胞分裂，以防止基因受损细胞的累积。在HSCs中抑制p53依赖性细胞特异性衰老可增强肝纤维化，相对应地，p53信号通路介导的衰老能够抑制活化的肝星状细胞增殖，减轻小鼠肝纤维化程度，因此诱导 HSCs 衰老可能作为纤维化逆转策略 [<xref ref-type="bibr" rid="hanspub.41392-ref31">31</xref>]。衰老的HSCs停止增殖，并能增强NK细胞的功能，促进免疫细胞的积累，加速其清除，同时能够上调基质降解酶的表达，下调ECM蛋白的表达，减少细胞外基质的产生，以控制和/或逆转纤维化 [<xref ref-type="bibr" rid="hanspub.41392-ref32">32</xref>]。</p></sec></sec></sec><sec id="s8"><title>4. 针对HSCs进行的肝纤维化的治疗</title><p>理想的抗纤维化治疗应该是肝脏特异性的，在长时间使用时耐受性良好，在不影响正常ECM合成的情况下有效减少过量胶原沉积。无论是运用于临床的还是尚处于动物实验阶段，针对肝纤维化有大量的治疗策略，其中病因治疗是肝纤维化治疗的首选，但是仍然存在许多无法针对病因治疗的肝纤维化，那么抗纤维化治疗就显得格外重要，在抗纤维化治疗中通过促进HSCs细胞凋亡，调节活化和/或增殖，来抑制活化的HSCs积累是一种重要的策略。但需要指出，目前尚无有效和公认的抗肝纤维化化学药物或生物制剂。</p><p>卡维地洛已被认定为治疗肝纤维化的有前途的药物，实验研究卡维地洛对人肝星状细胞LX-2自噬和凋亡的影响，研究发现：卡维地洛处理的细胞与对照细胞相比，表现出典型的自噬小体的超微结构，且拥有较高的自噬标记物水平，提示卡维地洛治疗可导致小鼠细胞自噬体数量增加。而这种自噬体数量的增加是由于自噬潮受损，自噬体的形成并未增加，而是自噬小体降解减少反向抑制自噬，而抑制自噬可降低HSCs增殖，促进HSCs凋亡。以此同时，卡维地洛也能直接降低Lx-2细胞活力并促进凋亡 [<xref ref-type="bibr" rid="hanspub.41392-ref33">33</xref>]。富马酸丙酚替诺福韦(tenofovir alafenamide fumarate, TAF)和富马酸替诺福韦酯(tenofovir disoproxil fumarate, TDF)作为抗乙肝药物，在抗纤维化方面也有一定作用，学者通过研究发现，TAF/TDF能够通过TGFβ1/Smad3和NF-κB/NLRP3炎症小体信号通路，阻止肝脏纤维化的进展和促进肝脏纤维化的逆转。TAF/TDF也能够调节HSCs的分化、激活和增殖。这些结果为TAF/TDF作为一种新的有前途的治疗肝脏纤维化的策略提供了有力的证据 [<xref ref-type="bibr" rid="hanspub.41392-ref34">34</xref>] [<xref ref-type="bibr" rid="hanspub.41392-ref35">35</xref>]。</p><p>近年来，天然产物在预防和治疗肝纤维化方面引起了广泛关注。广为人知的青蒿素(artemisinin)除被用于疟疾治疗外，其衍生物二氢青蒿素(dihydroartemisinin, DHA)还具有抗炎、调节免疫和抑制疤痕的作用，并且DHA 能够保护肝脏因BDL所导致的损伤和纤维化，抑制HSCs 增殖，扰乱PDGF-βR/ERK信号通路所介导的HCSs活化，经人HSC细胞系(LX-2)和分离大鼠原代HSCs验证，DHA能够以剂量依赖性和时间依赖性的方式对HSCs产生抗增殖作用 [<xref ref-type="bibr" rid="hanspub.41392-ref36">36</xref>]。有学者从山芝麻这种广泛用于肝病治疗的草药中分离出一种活性成分，并将其鉴定为山芝麻酸甲酯(methyl helicterate, MH)，发现MH能通过抑制氧化应激和NF-κB激活，显著缓解CCl4诱导的大鼠肝损伤，而其对肝纤维化的逆转，主要是诱导HSCs凋亡和自噬性细胞死亡 [<xref ref-type="bibr" rid="hanspub.41392-ref37">37</xref>]。此外，从柳珊瑚中提取的珊瑚碱(pin)能够降低肝星状细胞的存活率，学者使用HSC-T6大鼠肝星状细胞进行研究发现，pin能够依赖caspase-3、ROS和ERK/jnk介导的细胞凋亡，抑制HSCs的细胞活力 [<xref ref-type="bibr" rid="hanspub.41392-ref38">38</xref>]。</p><p>除天然产物提取物外，尚存在一些合成产物具有潜在的抗纤维化作用。甲基阿魏酸(Methyl ferulic acid, MFA)，是一种具有生物活性的单体，在体外实验中，MFA能够抑制TGF-β1诱导的HSCs激活，在体外实验中，能够有效地缓解纤维化大鼠模型肝脏的纤维化程度，而这种抗纤维化作用，是通过抑制TGF-β1/Smad信号通路，从而减少肝星状细胞激活，缓解肝纤维化 [<xref ref-type="bibr" rid="hanspub.41392-ref39">39</xref>]。Reversin是一种合成的2,6-二代嘌呤类似物，研究数据表明，在G2/M期，它诱导了HSCs的形态变化，抑制了细胞增殖，并诱导细胞周期停滞，Reversin可能是肝纤维化逆转的一种很有前景的药物，因为它能诱导HSCs凋亡，抑制细胞增殖，减少HSCs活化，并在体外降解细胞外基质 [<xref ref-type="bibr" rid="hanspub.41392-ref40">40</xref>]。这些药物的细胞动物实验结果都能为我们研究更加有效的抗纤维化药物提供指导。</p></sec><sec id="s9"><title>5. 总结与展望</title><p>虽然肝纤维化发病机制和逆转研究取得明显进展，但肝纤维化过程极为复杂，影响因素重多，而HSCs作为这一过程的中心环节，在肝纤维化的过程发挥起始作用；抑制HSCs的活化和增殖，活化HSCs清除，凋亡和衰老等机制经研究证明能促进肝纤维化的逆转。目前将HSCs作为肝纤维化治疗的靶点已取得了可观的效果，但绝大部分研究仍处于动物实验阶段，临床实验尚不足，仍需要进一步的研究，同时应该进一步完善肝纤维化的分子机制探索，探寻适用于肝纤维化患者的临床治疗的药物。如前文所述，在肝纤维化的发生发展中，HSCs只是其中一个重要环节，仍受其他众多因素的影响，因此应注重各因素之间的相互作用，探索更加有效的抗肝纤维化方案。</p></sec><sec id="s10"><title>文章引用</title><p>郑万明,吴怡林,龚建平. 肝星状细胞与肝纤维化及其逆转的研究进展Advances in Hepatic Stellate Cells and Hepatic Fibrosis and Its Reverse[J]. 临床医学进展, 2021, 11(03): 1420-1428. https://doi.org/10.12677/ACM.2021.113204</p></sec><sec id="s11"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.41392-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Li, D., Li, W., Chen, Y., Liu, L., Ma, D., Wang, H., et al. (2018) Anti-Fibrotic Role and Mechanism of Periplaneta americana Extracts in CCl4-Induced Hepatic Fibrosis in Rats. Acta Biochimica et Biophysica Sinica, 50, 491-498. 
&lt;br&gt;https://doi.org/10.1093/abbs/gmy024</mixed-citation></ref><ref id="hanspub.41392-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Asrani, S.K., Devarbhavi, H., Eaton, J. and Kamath, P.S. (2019) Burden of Liver Diseases in the World. Journal of Hepatology, 70, 151-171. &lt;br&gt;https://doi.org/10.1016/j.jhep.2018.09.014</mixed-citation></ref><ref id="hanspub.41392-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Tsuchida, T. and Friedman, S.L. (2017) Mechanisms of Hepatic Stellate Cell Activation. Nature Reviews Gastroenterology &amp; Hepatology, 14, 397-411. &lt;br&gt;https://doi.org/10.1038/nrgastro.2017.38</mixed-citation></ref><ref id="hanspub.41392-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Shajari, S., Saeed, A., Smith-Cortinez, N.F., Heegsma, J., Sydor, S. and Nico Faber, K. (2019) Hormone-Sensitive Lipase Is a Retinyl Ester Hydrolase in Human and Rat Quiescent Hepatic Stellate Cells. Biochimica et Biophysica Acta (BBA)-Molecular and Cell Biology of Lipids, 1864, 1258-1267. &lt;br&gt;https://doi.org/10.1016/j.bbalip.2019.05.012</mixed-citation></ref><ref id="hanspub.41392-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Lepreux, S. and DesmoulièRE, A. (2015) Human Liver Myofibroblasts During Development and Diseases with a Focus on Portal (myo)Fibroblasts. Frontiers in Physiology, 6, 173. &lt;br&gt;https://doi.org/10.3389/fphys.2015.00173</mixed-citation></ref><ref id="hanspub.41392-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Li, D., He, L., Guo, H., Chen, H. and Shan, H. (2015) Targeting Activated Hepatic Stellate Cells (aHSCs) for Liver Fibrosis Imaging. EJNMMI Research, 5, Article No. 71. &lt;br&gt;https://doi.org/10.1186/s13550-015-0151-x</mixed-citation></ref><ref id="hanspub.41392-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Li, X., Wang, Y., Wang, H., Huang, C., Huang, Y. and Li, J. (2015) Endoplasmic Reticulum Stress Is the Crossroads of Autophagy, Inflammation, and Apoptosis Signaling Pathways and Participates in Liver Fibrosis. Inflammation Research, 64, 1-7. &lt;br&gt;https://doi.org/10.1007/s00011-014-0772-y</mixed-citation></ref><ref id="hanspub.41392-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Yoshida, K., Matsuzaki, K., Murata, M., Yamaguchi, T., Suwa, K. and Okazaki, K. (2018) Clinico-Pathological Importance of TGF-β/Phospho-Smad Signaling during Human Hepatic Fibrocarcinogenesis. Cancers, 10, 183.  
&lt;br&gt;https://doi.org/10.3390/cancers10060183</mixed-citation></ref><ref id="hanspub.41392-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Liu, Y.T., Heller, M., Meng, Z., Yu, L.-R., Tang, Y., Zhou, M., et al. (2017) Transforming Growth Factor-β (TGF-β) Directly Activates the JAK1-STAT3 Axis to Induce Hepatic Fibrosis in Coordination with the SMAD Pathway. Journal of Biological Chemistry, 292, 4302-4312. &lt;br&gt;https://doi.org/10.1074/jbc.M116.773085</mixed-citation></ref><ref id="hanspub.41392-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">El-Wakeel, S.A., Rahmo, R.M. and El-Abhar, H.S. (2018) Anti-Fibrotic Impact of Carvedilol in a CCl-4 Model of Liver Fibrosis via Serum microRNA-200a/SMAD7 Enhancement to Bridle TGF-β1/EMT Track. Scientific Reports, 8, Article No. 14327. &lt;br&gt;https://doi.org/10.1038/s41598-018-32309-1</mixed-citation></ref><ref id="hanspub.41392-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Kostallari, E., Hirsova, P., Prasnicka, A., Verma, V.K., Yaqoob, U., Wongjarupong, N., et al. (2018) Hepatic Stellate Cell-Derived Platelet-Derived Growth Factor Receptor-Alpha-Enriched Extracellular Vesicles Promote Liver Fibrosis in Mice through SHP2. Hepatology, 68, 333-348. &lt;br&gt;https://doi.org/10.1002/hep.29803</mixed-citation></ref><ref id="hanspub.41392-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Ying, H.Z., Chen, Q., Zhang, W.Y., Zhang, H.-H., Ma, Y., Zhang, S.-Z., et al. (2017) PDGF Signaling Pathway in Hepatic Fibrosis Pathogenesis and Therapeutics (Review). Molecular Medicine Reports, 16, 7879-7889. 
&lt;br&gt;https://doi.org/10.3892/mmr.2017.7641</mixed-citation></ref><ref id="hanspub.41392-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Lim, B.J., Lee, W.K., Lee, H.W., Lee, K.S., Kim, J.K., Chang, H.Y., et al. (2018) Selective Deletion of Hepatocyte Platelet-Derived Growth Factor Receptor α and Development of Liver Fibrosis in Mice. Cell Communication and Signaling, 16, Article No. 93. &lt;br&gt;https://doi.org/10.1186/s12964-018-0306-2</mixed-citation></ref><ref id="hanspub.41392-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Kikuchi, A., Pradhan-Sundd, T., Singh, S., Nagarajan, S., Loizos, N. and Monga, S.P. (2017) Platelet-Derived Growth Factor Receptor α Contributes to Human Hepatic Stellate Cell Proliferation and Migration. American Journal of Pathology, 187, 2273-2287. &lt;br&gt;https://doi.org/10.1016/j.ajpath.2017.06.009</mixed-citation></ref><ref id="hanspub.41392-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Taniguchi, K. and Karin, M. (2018) NF-κB, Inflammation, Immunity and Cancer: Coming of Age. Nature Reviews Immunology, 18, 309-324. &lt;br&gt;https://doi.org/10.1038/nri.2017.142</mixed-citation></ref><ref id="hanspub.41392-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Zhu, Z.X., Zhu, L.L., Cheng, Z., Zhao, X.-K., Liu, Y.-M., Fan, L.-D., et al. (2019) Cellular Mechanism of Tβ4 Intervention in Liver Fibrosis by Regulating NF-κB Signaling Pathway. European Review for Medical and Pharmacological Sciences, 23, 1279-1290. &lt;br&gt;https://doi.org/10.26355/eurrev_201902_17023</mixed-citation></ref><ref id="hanspub.41392-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Seki, E., De Minicis, S., Osterreicher, C.H., Kluwe, J., Osawa, Y., Brenner, D.A., et al. (2007) TLR4 Enhances TGF-β Signaling and Hepatic Fibrosis. Nature Medicine, 13, 1324-1332. &lt;br&gt;https://doi.org/10.1038/nm1663</mixed-citation></ref><ref id="hanspub.41392-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Zoubek, M.E., Trautwein, C. and Strnad, P. (2017) Reversal of Liver Fibrosis: From Fiction to Reality. Best Practice &amp; Research Clinical Gastroenterology, 31, 129-141. &lt;br&gt;https://doi.org/10.1016/j.bpg.2017.04.005</mixed-citation></ref><ref id="hanspub.41392-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Jung, Y.K. and Yim, H.J. (2017) Reversal of Liver Cirrhosis: Current Evidence and Expectations. Korean Journal of Internal Medicine, 32, 213-228. &lt;br&gt;https://doi.org/10.3904/kjim.2016.268</mixed-citation></ref><ref id="hanspub.41392-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Ezhilarasan, D., Sokal, E. and Najimi, M. (2018) Hepatic Fibrosis: It Is Time to Go with Hepatic Stellate Cell-Specific Therapeutic Targets. Hepatobiliary &amp; Pancreatic Diseases International, 17, 192-197.  
&lt;br&gt;https://doi.org/10.1016/j.hbpd.2018.04.003</mixed-citation></ref><ref id="hanspub.41392-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Fan, W., Liu, T., Chen, W., Hammad, S., Longerich, T., Hausser, I., et al. (2019) ECM1 Prevents Activation of Transforming Growth Factor β, Hepatic Stellate Cells, and Fibrogenesis in Mice. Gastroenterology, 157, 1352-1367.e13.  
&lt;br&gt;https://doi.org/10.1053/j.gastro.2019.07.036</mixed-citation></ref><ref id="hanspub.41392-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Higashi, T., Friedman, S.L. and Hoshida, Y. (2017) Hepatic Stellate Cells as Key Target in Liver Fibrosis. Advanced Drug Delivery Reviews, 121, 27-42. &lt;br&gt;https://doi.org/10.1016/j.addr.2017.05.007</mixed-citation></ref><ref id="hanspub.41392-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Zhang, C., Liu, X.Q., Sun, H.N., Meng, X.-M., Bao, Y.-W., Zhang, H.-P, et al. (2018) Octreotide Attenuates Hepatic Fibrosis and Hepatic Stellate Cells Proliferation and Activation by Inhibiting Wnt/β-Catenin Signaling Pathway, c-Myc and cyclin D1. International Immunopharmacology, 63, 183-190. &lt;br&gt;https://doi.org/10.1016/j.intimp.2018.08.005</mixed-citation></ref><ref id="hanspub.41392-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Yu, H.X., Yao, Y., Bu, F.T., Chen, Y., Wu, Y.-T., Yang, Y., et al. (2019) Blockade of YAP Alleviates Hepatic Fibrosis through Accelerating Apoptosis and Reversion of Activated Hepatic Stellate Cells. Molecular Immunology, 107, 29-40. &lt;br&gt;https://doi.org/10.1016/j.molimm.2019.01.004</mixed-citation></ref><ref id="hanspub.41392-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Ma, P.F., Gao, C.C., Yi, J., Zhao, J.-L., Liang, S.-Q., Zhao, Y., et al. (2017) Cytotherapy with M1-Polarized Macrophages Ameliorates Liver Fibrosis by Modulating Immune Microenvironment in Mice. Journal of Hepatology, 67, 770-779. &lt;br&gt;https://doi.org/10.1016/j.jhep.2017.05.022</mixed-citation></ref><ref id="hanspub.41392-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Moroni, F., Dwyer, B.J., Graham, C., Pass, C., Bailey, L., Ritchie, L, et al. (2019) Safety Profile of Autologous Macrophage Therapy for Liver Cirrhosis. Nature Medicine, 25, 1560-1565. &lt;br&gt;https://doi.org/10.1038/s41591-019-0599-8</mixed-citation></ref><ref id="hanspub.41392-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Gao, B., Radaeva, S. (2013) Natural Killer and Natural Killer T Cells in Liver Fibrosis. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease, 1832, 1061-1069. &lt;br&gt;https://doi.org/10.1016/j.bbadis.2012.09.008</mixed-citation></ref><ref id="hanspub.41392-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Wen, J., Zhou, Y., Wang, J., Chen, J., Yan, W., Wu, J., et al. (2017) Retracted Article: Interactions between Th1 Cells and Tregs Affect Regulation of Hepatic Fibrosis in biliary atresia through the IFN-γ/STAT1 Pathway. Cell Death Differ, 24, 997-1006. &lt;br&gt;https://doi.org/10.1038/cdd.2017.31</mixed-citation></ref><ref id="hanspub.41392-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">de Oliveira da Silva, B., Ramos, L.F. and Moraes, K. (2017) Molecular Interplays in Hepatic Stellate Cells Apoptosis, Senescence and Phenotype Reversion as Cellular Connections That Modulates Liver Fibrosis. Cell Biology International, 41, 946-959. &lt;br&gt;https://doi.org/10.1002/cbin.10790</mixed-citation></ref><ref id="hanspub.41392-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">Ding, Q., Xie, X.L., Wang, M.M., Yin, J., Tian, J.-M., Jiang, X.-Y., et al. (2019) The Role of the Apoptosis-Related Protein BCL-B in the Regulation of Mitophagy in Hepatic Stellate Cells during the Regression of Liver Fibrosis. Experimental &amp; Molecular Medicine, 51, 1-13. &lt;br&gt;https://doi.org/10.1038/s12276-018-0199-6</mixed-citation></ref><ref id="hanspub.41392-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">Tsuchida, T. (2019) Mechanisms of Hepatic Stellate Cell Activation as a Therapeutic Target for the Treatment of Non-Alcoholic Steatohepatitis. Nihon Yakurigaku Zasshi, 154, 203-209.  
&lt;br&gt;https://doi.org/10.1254/fpj.154.203</mixed-citation></ref><ref id="hanspub.41392-ref32"><label>32</label><mixed-citation publication-type="other" xlink:type="simple">Panebianco, C., Oben, J.A., Vinciguerra, M. and Pazienza, V. (2017) Senescence in Hepatic Stellate Cells as a Mechanism of Liver Fibrosis Reversal: A Putative Synergy between Retinoic acid and PPAR-Gamma Signalings. Clinical and Experimental Medicine, 17, 269-280. &lt;br&gt;https://doi.org/10.1007/s10238-016-0438-x</mixed-citation></ref><ref id="hanspub.41392-ref33"><label>33</label><mixed-citation publication-type="other" xlink:type="simple">Meng, D., Li, Z., Wang, G., Ling, L., Wu, Y. and Zhang, C. (2018) Carvedilol Attenuates Liver Fibrosis by Suppressing Autophagy and Promoting Apoptosis in Hepatic Stellate Cells. Biomedicine &amp; Pharmacotherapy, 108, 1617-1627.  
&lt;br&gt;https://doi.org/10.1016/j.biopha.2018.10.005</mixed-citation></ref><ref id="hanspub.41392-ref34"><label>34</label><mixed-citation publication-type="other" xlink:type="simple">Zhao, J., Han, M., Zhou, L., Liang, P., Wang, Y., Feng, S., et al. (2020) TAF and TDF Attenuate Liver Fibrosis through NS5ATP9, TGFβ1/Smad3, and NF-κB/NLRP3 Inflammasome Signaling Pathways. Hepatology International, 14, 145-160. &lt;br&gt;https://doi.org/10.1007/s12072-019-09997-6</mixed-citation></ref><ref id="hanspub.41392-ref35"><label>35</label><mixed-citation publication-type="other" xlink:type="simple">Rockey, D.C. (2016) Liver Fibrosis Reversion after Suppression of Hepatitis B Virus. Clinics in Liver Disease, 20, 667-679. &lt;br&gt;https://doi.org/10.1016/j.cld.2016.06.003</mixed-citation></ref><ref id="hanspub.41392-ref36"><label>36</label><mixed-citation publication-type="other" xlink:type="simple">Chen, Q., Chen, L., Kong, D., Shao, J., Wu, L. and Zheng, S. (2016) Dihydroartemisinin Alleviates Bile Duct Ligation-Induced Liver Fibrosis and Hepatic Stellate Cell Activation by Interfering with the PDGF-βR/ERK Signaling Pathway. International Immunopharmacology, 34, 250-258. &lt;br&gt;https://doi.org/10.1016/j.intimp.2016.03.011</mixed-citation></ref><ref id="hanspub.41392-ref37"><label>37</label><mixed-citation publication-type="other" xlink:type="simple">Zhang, X.L., Chen, Z.N., Huang, Q.F., Bai, F.-C., Nie, J.-L., Lu, S.-J., et al. (2018) Methyl Helicterate Inhibits Hepatic Stellate Cell Activation through Modulation of Apoptosis and Autophagy. Cellular Physiology and Biochemistry, 51, 897-908. &lt;br&gt;https://doi.org/10.1159/000495390</mixed-citation></ref><ref id="hanspub.41392-ref38"><label>38</label><mixed-citation publication-type="other" xlink:type="simple">Kuo, L.M., Chen, P.J., Sung, P.J., Chang, Y.-C., Ho, C.-T, Wu, Y.-H., et al. (2018) The Bioactive Extract of Pinnigorgia sp. Induces Apoptosis of Hepatic Stellate Cells via ROS-ERK/JNK-Caspase-3 Signaling. Marine Drugs, 16, Article No. 19. &lt;br&gt;https://doi.org/10.3390/md16010019</mixed-citation></ref><ref id="hanspub.41392-ref39"><label>39</label><mixed-citation publication-type="other" xlink:type="simple">Cheng, Q., Li, C., Yang, C.F., Zhong, Y.J., Wu, D., Shi, L., et al. (2019) Methyl Ferulic Acid Attenuates Liver Fibrosis and Hepatic Stellate Cell Activation through the TGF-β1/Smad and NOX4/ROS Pathways. Chemico-Biological Interactions, 299, 131-139. &lt;br&gt;https://doi.org/10.1016/j.cbi.2018.12.006</mixed-citation></ref><ref id="hanspub.41392-ref40"><label>40</label><mixed-citation publication-type="other" xlink:type="simple">Huang, Y., Huang, D., Weng, J., Zhang, S., Zhang, Q., Mai, Z., et al. (2016) Effect of Reversine on Cell Cycle, Apoptosis, and Activation of Hepatic Stellate Cells. Molecular and Cellular Biochemistry, 423, 9-20.  
&lt;br&gt;https://doi.org/10.1007/s11010-016-2815-x</mixed-citation></ref></ref-list></back></article>